Investment in COVID-19 testing & diagnostics
FIND is co-convener, together with The Global Fund, of the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Partnership. The ACT Accelerator is a global collaboration to accelerate the development, production and equitable access to new COVID-19 diagnostics, therapeutics and vaccines.
On 4 May 2020, FIND CEO Catharina Boehme spoke at the Coronavirus Global Response pledging event, calling on the global community and political leaders to support this landmark collaboration, and for donors to provide the necessary resources so that testing inequalities do not jeopardize our global pandemic response.
On 28 May 2020, Global Citizen and the European Commission announced a new campaign, Global Goal: Unite for Our Future, whose aim is to ensure that everyone, everywhere in the world, has access to COVID-19 tests, treatments, and vaccines. This campaign also seeks to lessen the impact of COVID-19 on the world’s most vulnerable people, ensuring they still have access to education, clean water, and more. The campaign, launched under the patronage of European Commission President Ursula von der Leyen, will focus on the development of tools to tackle COVID-19, and ensuring that these tools are available to all communities equally, as well as mitigating the impacts of COVID-19 on those living in poverty.
Investment for diagnostics & testing committed by:
COVID-19 diagnostics & testing investment case
We have an opportunity to contain the humanitarian and economic fallout of the COVID-19 pandemic. Without mass testing – which relies on availability of high-performing, rapid tests – the disease will continue to spread. Innovation and scale up of these tests must be accelerated for deployment in all countries. For low- and middle-income countries, this investment would contribute to saving 9 million lives, and strengthen health systems to overcome the COVID-19 pandemic.
An investment of US$6 billion is required to harness innovation and secure access to vital diagnostic tests over the next 12 months for low- and middle-income countries.
US$2 billion of this is required immediately to expedite development, manufacturing and scale-up of the rapid tests that will enable mass testing to be introduced globally – as well as procurement of tests to fill critical short-term gaps in low-income countries.
For more information, or to discuss how you can support diagnostics and testing for COVID-19, please contact us.